907 related articles for article (PubMed ID: 20632993)
21. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
[TBL] [Abstract][Full Text] [Related]
22. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Itk tyrosine kinase: contribution of noncatalytic domains to enzymatic activity.
Hawkins J; Marcy A
Protein Expr Purif; 2001 Jul; 22(2):211-9. PubMed ID: 11437596
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of the ARF-GAP domain and ankyrin repeats of PYK2-associated protein beta.
Mandiyan V; Andreev J; Schlessinger J; Hubbard SR
EMBO J; 1999 Dec; 18(24):6890-8. PubMed ID: 10601011
[TBL] [Abstract][Full Text] [Related]
25. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
[TBL] [Abstract][Full Text] [Related]
26. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
27. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
Mathivet T; Mazot P; Vigny M
Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
[TBL] [Abstract][Full Text] [Related]
28. Translocations involving anaplastic lymphoma kinase (ALK).
Duyster J; Bai RY; Morris SW
Oncogene; 2001 Sep; 20(40):5623-37. PubMed ID: 11607814
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of PTP-SL/PTPBR7 catalytic domain: implications for MAP kinase regulation.
Szedlacsek SE; Aricescu AR; Fulga TA; Renault L; Scheidig AJ
J Mol Biol; 2001 Aug; 311(3):557-68. PubMed ID: 11493009
[TBL] [Abstract][Full Text] [Related]
31. Protein tyrosine kinase-substrate interactions.
Bose R; Holbert MA; Pickin KA; Cole PA
Curr Opin Struct Biol; 2006 Dec; 16(6):668-75. PubMed ID: 17085043
[TBL] [Abstract][Full Text] [Related]
32. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Bischof D; Pulford K; Mason DY; Morris SW
Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.
Koshiba S; Li H; Motoda Y; Tomizawa T; Kasai T; Tochio N; Yabuki T; Harada T; Watanabe S; Tanaka A; Shirouzu M; Kigawa T; Yamamoto T; Yokoyama S
J Struct Funct Genomics; 2010 Jun; 11(2):125-41. PubMed ID: 20454865
[TBL] [Abstract][Full Text] [Related]
34. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
[TBL] [Abstract][Full Text] [Related]
35. Subdomain switching reveals regions that harbor substrate specificity and regulatory properties of protein tyrosine kinases.
Wang YH; Huang K; Lin X; Sun G
Biochemistry; 2007 Sep; 46(35):10162-9. PubMed ID: 17691821
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
37. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).
Morris SW; Naeve C; Mathew P; James PL; Kirstein MN; Cui X; Witte DP
Oncogene; 1997 May; 14(18):2175-88. PubMed ID: 9174053
[TBL] [Abstract][Full Text] [Related]
38. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
Elling RA; Fucini RV; Romanowski MJ
Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
40. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
